Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Tokai University School of Medicine, Isehara, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:5City/State/Province:Isehara
Treatments:ChemotherapyHospital:Tokai University School of Medicine
Drugs:Journal:Link
Date:Nov 2010

Description:

Patients:
This phase 2 study involved 62 women with metastatic breast cancer who had previously been treated with anthracycline and taxane drugs. The median age of the group was 53 years with a range of 25-74.

Treatment:
Patients in this study were treated with the chemotherapy agent gemcitabine.

Toxicities:
One patient died of acute respiratory failure during this study. In addition, 58.1% of patients experienced grade 3 or 4 neutropenia. Anorexia and malaise (any grade) was reported by 45.2% of patients.

Results:
The median overall survival reported in this study was 17.8 months.

Support:
This study was funded by Eli Lilly, makers of gemcitabine (brand name: Gemzar).

Correspondence: Dr. Yasuhiro Suzuki; email: [email protected]



Back